SDTNBI: An integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning

Briefings in Bioinformatics

Volumn 18, Issue 2, 2017, Pages 333-347

  Wu, Zengrui ^a   Cheng, Feixiong ^b   Li, Jie ^a   Li, Weihua ^a   Liu, Guixia ^a   Tang, Yun ^a,c  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NORTHEASTERN UNIVERSITY   (United States)

^c Shanghai Key Laboratory of New Drug Design   (China)

Author keywords

Chemical substructure; Chemoinformatics; Drug repositioning; Drug target interaction; Failed drug; Network based inference

Indexed keywords

COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG REPOSITIONING; RECEIVER OPERATING CHARACTERISTIC;

COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG REPOSITIONING; ROC CURVE;

EID: 85018398974     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbw012     Document Type: Article

References (76)

1. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discou Today 2005;10:139-47.
2. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90.
3. Cheng FX, Li WH, Wu ZR, et al. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. J Chem Inf Model 2013;53:753-62.
4. Cheng FX, Li WH, Zhou YD, et al. Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). Mol Biosyst 2013;9:1316-25.
5. Li J, Wu ZR, Cheng FX, et al. Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology. Sci Rep 2014;4:5576.
6. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011;12:303-11.
7. Ding H, Takigawa I, Mamitsuka H, et al. Similarity-based machine learning methods for predicting drug-target interactions: a brief review. Brief Bioinform 2014;15:734-47.
8. Li HL, Gao ZT, Kang L, et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006;34:W219-24.
9. Luo H, Chen J, Shi LM, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res 2011;39:W492-8.
10. Cheng FX, Zhou YD, Li J, et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst 2012;8:2373-84.
11. Yamanishi Y, Araki M, Gutteridge A, et al. Prediction of drugtarget interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008;24:1232-40.
12. Yamanishi Y, Kotera M, Kanehisa M, et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010;26:i246-54.
13. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197-206.
14. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81.
15. Cheng FX, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comp Biol 2012;8:e1002503.
16. Cheng FX, Zhou YD, Li WH, et al. Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One 2012;7:e41064.
17. Alaimo S, Pulvirenti A, Giugno R, et al. Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics 2013;29:2004-8.
18. Chen X, Liu MX, Yan GY. Drug-target interaction prediction by random walk on the heterogeneous network. Mol Biosyst 2012;8:1970-8.
19. Lucas X, Gruning BA, Bleher S, et al. The purchasable chemical space: a detailed picture. JChem InfModel 2015;55:915-24.
20. Overington JP, Al-Lazikani B, Hopkins AL. Opinion - how many drug targets are there? Nat Reu Drug Discou 2006;5: 993-6.
21. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51.
22. Mullard A. Drug repurposing programmes get lift off. Nat Reu Drug Discou 2012;11:1-2.
23. Shen J, Cheng FX, Xu Y, et al. Estimation of ADME properties with substructure pattern recognition. J Chem Inf Model 2010;50:1034-41.
24. Yamanishi Y, Pauwels E, Saigo H, et al. Extracting sets of chemical substructures and protein domains governing drugtarget interactions. JChem InfModel 2011;51:1183-94.
25. Klekota J, Roth FP. Chemical substructures that enrich forbiological activity. Bioinformatics 2008;24:2518-25.
26. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bio-activity database for drug discovery. Nucleic Acids Res 2012;40:D1100-7.
27. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res 2011;39:D1035-41.
28. Liu TQ, Lin YM, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198-201.
29. O'Boyle NM, Banck M, James CA, et al. Open Babel: an open chemical toolbox. JCheminform 2011;3:14.
30. Yap CW. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 2011;32:1466-74.
31. Cheng FX, Ikenaga Y, Zhou YD, et al. In silico assessment of chemical biodegradability. JChem InfModel 2012;52:655-69.
32. Rogers D, Hahn M. Extended-connectivity fingerprints. J Chem InfModel 2010;50:742-54.
33. Yera ER, Cleves AE, Jain AN. Chemical structural novelty: on-targets and off-targets. J Med Chem 2011;54:6771-85.
34. Lo YC, Senese S, Li CM, et al. Large-scale chemical similarity networks for target profiling of compounds identified in cell-based chemical screens. PLoS Comp Biol 2015;11:e1004153.
35. Nan HM, Hutter CM, Lin Y, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015;313:1133-42.
36. Lu WQ, Cheng FX, Jiang J, et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci Rep 2015;5:8114.
37. Apweiler R, Bairoch A, Wu CH, et al. UniProt: the universal protein knowledgebase. Nucleic Acids Res 2004;32:D115-19.
38. Davis AP, Murphy CG, Saraceni-Richards CA, et al. Comparative toxicogenomics database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res 2009;37:D786-92.
39. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
40. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
41. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxy-genase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
42. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
43. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
44. Tucker ON, Dannenberg AJ, Yang FK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
45. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
46. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
47. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
48. Dozmorov MG, Azzarello JT, Wren JD, et al. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan. BMC Cancer 2010;10:16.
49. Liu CF, Lou W, Zhu YZ, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res 2015;75:1413-22.
50. Yepuru M, Wu ZZ, Kulkarni A, et al. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res 2013;19:5613-25.
51. Inoue T, Anai S, Onishi S, et al. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol 2013;13:9
52. Wechter WJ, Leipold DD, Murray ED, et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-8.
53. John-Aryankalayil M, Palayoor ST, Cerna D, et al. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 2009;8:261-73.
54. Liedtke AJ, Adeniji AO, Chen M, et al. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17 beta-hydroxysteroid dehydrogenase/pros-taglandin F synthase) in castrate-resistant prostate cancer. J Med Chem 2013;56:2429-46.
55. Soriano-Hernandez AD, Galvan-Salazar HR, Montes-Galindo DA, et al. Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation. Int Urol Nephrol 2012;44:471-7.
56. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3 alpha-HSD, type 5 17 beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75:484-93.
57. Gobec S, Brozic P, Rizner TL. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. Bioorg Med Chem Lett 2005;15:5170-5.
58. Flanagan JU, Yosaatmadja Y, Teague RM, et al. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3. PLoS One 2012;7:16.
59. Lovering AL, Ride JP, Bunce CM, et al. Crystal structures of prostaglandin D-2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 2004;64:1802-10.
60. Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007;96:104-9.
61. Lou YM, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
62. Watson PH, Chia SK, Wykoff CC, et al. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer 2003;88:1065-70.
63. Barnett DH, Sheng S, Charn TH, et al. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res 2008;68:3505-15.
64. Takehara M, Hoshino T, Namba T, et al. Acetaminopheninduced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice. Biochem Pharmacol 2011;81:1124-35.
65. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004;47:550-7.
66. Di Fiore A, Pedone C, D'Ambrosio K, et al. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib. Bioorg Med Chem Lett 2006;16:437-42.
67. Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Biorg Med Chem 2008;16:7424-8.
68. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
69. DuJY, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
70. Lee E, Son JE, Byun S, et al. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol Appl Pharmacol 2013;272:12-20.
71. Khwaia FS, Quann EJ, Pattabiraman N, et al. Carprofen induction of p75(NTR)-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 2008;7:3539-45.
72. Cheng JD, Imanishi H, Liu WD, et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004;95:666-73.
73. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib - potential value as adjuvant therapy after surgery. Ann Surg 2005;241:168-78.
74. Cheng FX, Li WH, Wang XC, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model 2013;53:744-52.
75. Mandl KD, Kohane IS. Federalist principles for healthcare data networks. Nat Biotechnol 2015;33:360-3.
76. Hewett M, Oliver DE, Rubin DL, et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res 2002;30:163-5.